The Metabolic Syndrome and Its Influence on Nonalcoholic Steatohepatitis

Clinics in Liver Disease

Volumn 20, Issue 2, 2016, Pages 225-243

  Kanwar, Pushpjeet ^a   Kowdley, Kris V ^b  

^a NEW YORK METHODIST HOSPITAL   (United States)

^b SWEDISH MEDICAL CENTER   (United States)

Author keywords

Hepatocellular carcinoma; Metabolic syndrome; NAFLD; Nonalcoholic steatohepatitis; Risk factors

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPOCYTOKINE; ADIPONECTIN; ALPHA TOCOPHEROL; EZETIMIBE; FATTY ACID; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; I KAPPA B KINASE BETA; INSULIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; LEPTIN; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; STRESS ACTIVATED PROTEIN KINASE; TELMISARTAN; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 9; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; VALSARTAN;

BARIATRIC SURGERY; BLOOD PRESSURE; BODY MASS; DIET; DIET THERAPY; DISEASE ASSOCIATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; GENETIC POLYMORPHISM; GLUCOSE INTOLERANCE; HEPATITIS; HEREDITY; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; INSULIN RESISTANCE; KINESIOTHERAPY; LIFESTYLE MODIFICATION; LIVER CELL; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; METABOLIC SYNDROME X; MORTALITY; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; OXIDATIVE STRESS; PATHOGENESIS; PREVALENCE; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; RISK FACTOR; SIGNAL TRANSDUCTION; STEATOSIS; WAIST CIRCUMFERENCE; WAIST HIP RATIO; COMORBIDITY; GENETICS; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOPHYSIOLOGY;

ADIPOKINES; COMORBIDITY; HUMANS; INSULIN RESISTANCE; METABOLIC SYNDROME X; NON-ALCOHOLIC FATTY LIVER DISEASE; RISK FACTORS;

EID: 84949894917     PISSN: 10893261     EISSN: 15578224     Source Type: Journal    
DOI: 10.1016/j.cld.2015.10.002     Document Type: Review

References (138)

1. Ford E.S. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care 2005, 28(7):1769-1778.
2. Reaven G.M. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988, 37(12):1595-1607.
3. Reaven G.M. Banting lecture 1988. Role of insulin resistance in human disease. 1988. Nutrition 1997, 13(1):65. [discussion: 64, 66].
4. Machado M., Cortez-Pinto H. Non-alcoholic steatohepatitis and metabolic syndrome. Curr Opin Clin Nutr Metab Care 2006, 9(5):637-642.
5. Chalasani N., Younossi Z., Levine J.E., et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012, 55(6):2005-2023.
6. Wong R.J., Ahmed A. Obesity and non-alcoholic fatty liver disease: disparate associations among Asian populations. World J Hepatol 2014, 6(5):263-273.
7. Neuschwander-Tetri B.A. Nonalcoholic steatohepatitis and the metabolic syndrome. Am J Med Sci 2005, 330(6):326-335.
8. Kleiner D.E., Brunt E.M., Van Natta M., et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005, 41(6):1313-1321.
9. Marchesini G., Bugianesi E., Forlani G., et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003, 37(4):917-923.
10. Alberti K.G., Eckel R.H., Grundy S.M., et al. Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; national heart, lung, and blood institute; American heart association; World heart federation; International atherosclerosis society; and International association for the study of obesity. Circulation 2009, 120(16):1640-1645.
11. Brunt E.M., Kleiner D.E., Wilson L.A., NASH Clinical Research Network (CRN), et al. Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology 2011, 53(3):810-820.
12. Beltrán-Sánchez H., Harhay M.O., Harhay M.M., et al. Prevalence and trends of metabolic syndrome in the adult U.S. population, 1999-2010. J Am Coll Cardiol 2013, 62(8):697-703.
13. Ford E.S., Li C., Zhao G. Prevalence and correlates of metabolic syndrome based on a harmonious definition among adults in the US. J Diabetes 2010, 2(3):180-193.
14. Smits M.M., Ioannou G.N., Boyko E.J., et al. Non-alcoholic fatty liver disease as an independent manifestation of the metabolic syndrome: results of a US national survey in three ethnic groups. J Gastroenterol Hepatol 2013, 28(4):664-670.
15. Cameron A.J., Shaw J.E., Zimmet P.Z. The metabolic syndrome: prevalence in worldwide populations. Endocrinol Metab Clin North Am 2004, 33(2):351-375.
16. Vernon G., Baranova A., Younossi Z.M. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011, 34(3):274-285.
17. Farrell G.C., Larter C.Z. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006, 43(2 Suppl 1):S99-S112.
18. McCullough A.J. The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease. Clin Liver Dis 2004, 8:521-533.
19. Mohan V., Farooq S., Deepa M., et al. Prevalence of non-alcoholic fatty liver disease in urban south Indians in relation to different grades of glucose intolerance and metabolic syndrome. Diabetes Res Clin Pract 2009, 84(1):84-91.
20. Lee K., Sung J.A., Kim J.S., et al. The roles of obesity and gender on the relationship between metabolic risk factors and non-alcoholic fatty liver disease in Koreans. Diabetes Metab Res Rev 2009, 25(2):150-155.
21. Akahoshi M., Amasaki Y., Soda M., et al. Correlation between fatty liver and coronary risk factors: a population study of elderly men and women in Nagasaki, Japan. Hypertens Res 2001, 24(4):337-343.
22. Duseja A., Singh S.P., Saraswat V.A., et al. Non-alcoholic fatty liver disease and metabolic syndrome-position paper of the Indian National Association for the Study of the Liver, Endocrine Society of India, Indian College of Cardiology and Indian Society of Gastroenterology. J Clin Exp Hepatol 2015, 5(1):51-68.
23. Reaven G.M. Insulin resistance, the insulin resistance syndrome, and cardiovascular disease. Panminerva Med 2005, 47(4):201-210.
24. Abate N., Garg A., Peshock R.M., et al. Relationship of generalized and regional adiposity to insulin sensitivity in men with NIDDM. Diabetes 1996, 45(12):1684-1693.
25. Gallagher E.J., Leroith D., Karnieli E. The metabolic syndrome-from insulin resistance to obesity and diabetes. Med Clin North Am 2011, 95(5):855-873.
26. Bugianesi E., Gastaldelli A., Vanni E., et al. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia 2005, 48(4):634-642.
27. Yamaguchi K., Yang L., McCall S., et al. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology 2007, 45(6):1366-1374.
28. Feldstein A.E., Werneburg N.W., Canbay A., et al. Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. Hepatology 2004, 40(1):185-194.
29. Pessayre D., Fromenty B. NASH: a mitochondrial disease. J Hepatol 2005, 42(6):928-940.
30. Charlton M., Krishnan A., Viker K., et al. Fast food diet mouse: novel small animal model of NASH with ballooning, progressive fibrosis, and high physiological fidelity to the human condition. Am J Physiol Gastrointest Liver Physiol 2011, 301(5):G825-G834.
31. Kohli R., Kirby M., Xanthakos S.A., et al. High-fructose, medium chain trans fat diet induces liver fibrosis and elevates plasma coenzyme Q9 in a novel murine model of obesity and nonalcoholic steatohepatitis. Hepatology 2010, 52(3):934-944.
32. Tetri L.H., Basaranoglu M., Brunt E.M., et al. Severe NAFLD with hepatic necroinflammatory changes in mice fed trans fats and a high-fructose corn syrup equivalent. Am J Physiol Gastrointest Liver Physiol 2008, 295(5):G987-G995.
33. Neuschwander-Tetri B.A., Ford D.A., Acharya S., et al. Dietary trans-fatty acid induced NASH is normalized following loss of trans-fatty acids from hepatic lipid pools. Lipids 2012, 47(10):941-950.
34. Mells J.E., Fu P.P., Kumar P., et al. Saturated fat and cholesterol are critical to inducing murine metabolic syndrome with robust nonalcoholic steatohepatitis. J Nutr Biochem 2015, 26(3):285-292.
35. Musso G., Gambino R., De Michieli F., et al. Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. Hepatology 2003, 37(4):909-916.
36. Petersen K.F., Dufour S., Hariri A., et al. Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease. N Engl J Med 2010, 362(12):1082-1089.
37. Romeo S., Kozlitina J., Xing C., et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008, 40(12):1461-1465.
38. Karpe F., Dickmann J.R., Frayn K.N. Fatty acids, obesity, and insulin resistance: time for a reevaluation. Diabetes 2011, 60(10):2441-2449.
39. Boden G., Lebed B., Schatz M., et al. Effects of acute changes of plasma free fatty acids on intramyocellular fat content and insulin resistance in healthy subjects. Diabetes 2001, 50(7):1612-1617.
40. Kelley D.E., Mokan M., Simoneau J.A., et al. Interaction between glucose and free fatty acid metabolism in human skeletal muscle. J Clin Invest 1993, 92(1):91-98.
41. LeRoith D., Cohen D.H. Obesity, type 2 diabetes, and cancer: the insulin and IGF connection. Endocr Relat Cancer 2012, 19(5):F27-F45.
42. Donnelly K.L., Smith C.I., Schwarzenberg S.J., et al. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 2005, 115(5):1343-1351.
43. Zarember K.A., Godowski P.J. Tissue expression of human Toll-like receptors and differential regulation of Toll-like receptor mRNAs in leukocytes in response to microbes, their products, and cytokines. J Immunol 2002, 168(2):554-561.
44. Jialal I., Huet B.A., Kaur H., et al. Increased toll-like receptor activity in patients with metabolic syndrome. Diabetes Care 2012, 35(4):900-904.
45. Bhargava P., Lee C.H. Role and function of macrophages in the metabolic syndrome. Biochem J 2012, 442(2):253-262.
46. Tsukumo D.M., Carvalho-Filho M.A., Carvalheira J.B., et al. Loss-of-function mutation in Toll-like receptor 4 prevents diet-induced obesity and insulin resistance. Diabetes 2007, 56(8):1986-1998.
47. Miura K., Kodama Y., Inokuchi S., et al. Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice. Gastroenterology 2010, 139(1):323-334.
48. Miura K., Seki E., Ohnishi H., et al. Role of toll-like receptors and their downstream molecules in the development of nonalcoholic fatty liver disease. Gastroenterol Res Pract 2010, 2010:362847.
49. Roth C.L., Elfers C.T., Figlewicz D.P., et al. Vitamin D deficiency in obese rats exacerbates nonalcoholic fatty liver disease and increases hepatic resistin and Toll-like receptor activation. Hepatology 2012, 55(4):1103-1111.
50. Buettner C., Muse E.D., Cheng A., et al. Leptin controls adipose tissue lipogenesis via central, STAT3-independent mechanisms. Nat Med 2008, 14(6):667-675.
51. Shimabukuro M., Koyama K., Chen G., et al. Direct antidiabetic effect of leptin through triglyceride depletion of tissues. Proc Natl Acad Sci U S A 1997, 94(9):4637-4641.
52. Kalra S.P. Disruption in the leptin-NPY link underlies the pandemic of diabetes and metabolic syndrome: new therapeutic approaches. Nutrition 2008, 24(9):820-826.
53. Münzberg H., Myers M.G. Molecular and anatomical determinants of central leptin resistance. Nat Neurosci 2005, 8(5):566-570.
54. Rabe K., Lehrke M., Parhofer K.G., et al. Adipokines and insulin resistance. Mol Med 2008, 14(11-12):741-751.
55. Chiturri S., Farrell G., Frost L., et al. Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: a manifestation of lipotoxicity?. Hepatology 2002, 36(2):403-409.
56. Yamauchi T., Kamon J., Waki H., et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001, 7(8):941-946.
57. Kondo H., Shimomura I., Matsukawa Y., et al. Association of adiponectin mutation with type 2 diabetes: a candidate gene for the insulin resistance syndrome. Diabetes 2002, 51(7):2325-2328.
58. Musso G., Gambino R., Biroli G., et al. Hypoadiponectinemia predicts the severity of hepatic fibrosis and pancreatic Beta-cell dysfunction in nondiabetic nonobese patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2005, 100(11):2438-2446.
59. Musso G., Gambino R., Durazzo M., et al. Adipokines in NASH: postprandial lipid metabolism as a link between adiponectin and liver disease. Hepatology 2005, 42(5):1175-1183.
60. Kaser S., Moschen A., Cayon A., et al. Adiponectin and its receptors in non-alcoholic steatohepatitis. Gut 2005, 54(1):117-121.
61. Handa P., Maliken B., Nelson J.E., et al. Reduced adiponectin signaling due to weight gain results in nonalcoholic steatohepatitis through impaired mitochondrial biogenesis. Hepatology 2014, 60(1):133-145.
62. Musso G., Cassader M., De Michieli F., et al. Nonalcoholic steatohepatitis versus steatosis: adipose tissue insulin resistance and dysfunctional response to fat ingestion predict liver injury and altered glucose and lipoprotein metabolism. Hepatology 2012, 56(3):933-942.
63. Tilg H., Diehl A.M. Cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med 2000, 343(20):1467-1476.
64. Li Z., Yang S., Lin H., et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 2003, 37(2):343-350.
65. Koves T.R., Ussher J.R., Noland R.C., et al. Mitochondrial overload and incomplete fatty acid oxidation contribute to skeletal muscle insulin resistance. Cell Metab 2008, 7(1):45-56.
66. Begricke K., Igoudjil A., Pessayre D., et al. Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it. Mitochondrion 2006, 6(1):1-28.
67. Asrih M., Jornayvaz F.R. Metabolic syndrome and nonalcoholic fatty liver disease: is insulin resistance the link?. Mol Cell Endocrinol 2015, [Epub ahead of print].
68. Gallagher E.J., Leroith D., Karnieli E. Insulin resistance in obesity as the underlying cause for the metabolic syndrome. Mt Sinai J Med 2010, 77(5):511-523.
69. Muoio D.M., Newgard C.B. Mechanisms of disease: molecular and metabolic mechanisms of insulin resistance and beta-cell failure in type 2 diabetes. Nat Rev Mol Cell Biol 2008, 9(3):193-205.
70. Tooke J.E., Hannemann M.M. Adverse endothelial function and the insulin resistance syndrome. J Intern Med 2000, 247(4):425-431.
71. DeFronzo R.A., Cooke C.R., Andres R., et al. The effect of insulin on renal handling of sodium, potassium, calcium, and phosphate in man. J Clin Invest 1975, 55(4):845-855.
72. Barbato A., Cappuccio F.P., Folkerd E.J., et al. Metabolic syndrome and renal sodium handling in three ethnic groups living in England. Diabetologia 2004, 47(1):40-46.
73. Massiera F., Bloch-Faure M., Ceiler D., et al. Adipose angiotensinogen is involved in adipose tissue growth and blood pressure regulation. FASEB J 2001, 15(14):2727-2729.
74. Rahmouni K., Correia M.L., Haynes W.G., et al. Obesity-associated hypertension: new insights into mechanisms. Hypertension 2005, 45(1):9-14.
75. Ginsberg H.N., Stalenhoef A.F. The metabolic syndrome: targeting dyslipidaemia to reduce coronary risk. J Cardiovasc Risk 2003, 10(2):121-128.
76. Lewis G.F., Uffelman K.D., Szeto L.W., et al. Interaction between free fatty acids and insulin in the acute control of very low density lipoprotein production in humans. J Clin Invest 1995, 95(1):158-166.
77. Kirk E.P., Klein S. Pathogenesis and pathophysiology of the cardiometabolic syndrome. J Clin Hypertens (Greenwich) 2009, 11(12):761-765.
78. Hopkins G.J., Barter P.J. Role of triglyceride-rich lipoproteins and hepatic lipase in determining the particle size and composition of high density lipoproteins. J Lipid Res 1986, 27(12):1265-1277.
79. Tilg H., Moschen A.R. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 2010, 52(5):1836-1846.
80. Ley R.E., Bäckhed F., Turnbaugh P. Obesity alters gut microbial ecology. Proc Natl Acad Sci U S A 2005, 102(31):11070-11075.
81. Ley R.E., Turnbaugh P.J., Klein S., et al. Microbial ecology: human gut microbes associated with obesity. Nature 2006, 444(7122):1022-1023.
82. Vrieze A., Van Nood E., Holleman F., et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 2012, 143(4):913-916.
83. Mattace Raso G., Simeoli R., Russo R., et al. Effects of sodium butyrate and its synthetic amide derivative on liver inflammation and glucose tolerance in an animal model of steatosis induced by high fat diet. PLoS One 2013, 8(7):e68626.
84. Marceau P., Biron S., Hould F.S. 1999 Liver pathology and the metabolic syndrome X in severe obesity. J Clin Endocrinol Metab 1999, 84(5):1513-1517.
85. Marchesini G., Brizi M., Bianchi G., et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001, 50(8):1844-1850.
86. Shen Y.H., Yang W.S., Lee L.T., et al. Bright liver and alanine aminotransferase are associated with metabolic syndrome in adults. Obes Res 2005, 13(7):1238-1245.
87. Bedogni G., Miglioli L., Masutti F., et al. Prevalence of and risk factors for nonalcoholic fatty liver disease: the dionysos nutrition and liver study. Hepatology 2005, 42(1):44-52.
88. Jung K.Y., Cho S.Y., Kim H.J., et al. Nonalcoholic steatohepatitis associated with metabolic syndrome: relationship to insulin resistance and liver histology. J Clin Gastroenterol 2014, 48(10):883-888.
89. Patton H.M., Yates K., Unalp-Arida A., et al. Association between metabolic syndrome and liver histology among children with nonalcoholic Fatty liver disease. Am J Gastroenterol 2010, 105(9):2093-2102.
90. Manco M., Marcellini M., Devito R., et al. Metabolic syndrome and liver histology in paediatric non-alcoholic steatohepatitis. Int J Obes (Lond) 2008, 32(2):381-387.
91. Uslusoy H.S., Nak S.G., Gülten M., et al. Liver histology according to the presence of metabolic syndrome in nonalcoholic fatty liver disease cases. World J Gastroenterol 2009, 15(9):1093-1098.
92. Huang H.L., Lin W.Y., Lee L.T., et al. Metabolic syndrome is related to nonalcoholic steatohepatitis in severely obese subjects. Obes Surg 2007, 17(11):1457-1463.
93. Ong J.P., Elariny H., Collantes R., et al. Predictors of nonalcoholic steatohepatitis and advanced fibrosis in morbidly obese patients. Obes Surg 2005, 15(3):310-315.
94. Kroh M., Liu R., Chand B. Laparoscopic bariatric surgery: what else are we uncovering? Liver pathology and preoperative indicators of advanced liver disease in morbidly obese patients. Surg Endosc 2007, 21(11):1957-1960.
95. Anty R., Iannelli A., Patouraux S., et al. A new composite model including metabolic syndrome, alanine aminotransferase and cytokeratin-18 for the diagnosis of non-alcoholic steatohepatitis in morbidly obese patients. Aliment Pharmacol Ther 2010, 32(11-12):1315-1322.
96. Wang Y., Li Y.Y., Nie Y.Q., et al. Association between metabolic syndrome and the development of non-alcoholic fatty liver disease. Exp Ther Med 2013, 6(1):77-84.
97. García-Monzón C., Martín-Pérez E., Iacono O.L., et al. Characterization of pathogenic and prognostic factors of nonalcoholic steatohepatitis associated with obesity. J Hepatol 2000, 33(5):716-724.
98. Dixon J.B., Bhathal P.S., O'Brien P.E. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001, 121(1):91-100.
99. Puljiz Z., Stimac D., Kovac D., et al. Predictors of nonalcoholic steatohepatitis in patients with elevated alanine aminotransferase activity. Coll Antropol 2010, 34(Suppl 1):33-37.
100. Ulitsky A., Ananthakrishnan A.N., Komorowski R., et al. A noninvasive clinical scoring model predicts risk of nonalcoholic steatohepatitis in morbidly obese patients. Obes Surg 2010, 20(6):685-691.
101. Campos G.M., Bambha K., Vittinghoff E., et al. A clinical scoring system for predicting nonalcoholic steatohepatitis in morbidly obese patients. Hepatology 2008, 47(6):1916-1923.
102. Haukeland J.W., Konopski Z., Linnestad P., et al. Abnormal glucose tolerance is a predictor of steatohepatitis and fibrosis in patients with non-alcoholic fatty liver disease. Scand J Gastroenterol 2005, 40(12):1469-1477.
103. Love-Osborne K.A., Nadeau K.J., Sheeder J., et al. Presence of the metabolic syndrome in obese adolescents predicts impaired glucose tolerance and nonalcoholic fatty liver disease. J Adolesc Health 2008, 42(6):543-548.
104. Zelber-Sagi S., Lotan R., Shibolet O., et al. Non-alcoholic fatty liver disease independently predicts prediabetes during a 7-year prospective follow-up. Liver Int 2013, 33(9):1406-1412.
105. Kasturiratne A., Weerasinghe S., Dassanayake A.S., et al. Influence of non-alcoholic fatty liver disease on the development of diabetes mellitus. J Gastroenterol Hepatol 2013, 28(1):142-147.
106. Marchesini G., Marzochhi R. Metabolic syndrome and NASH. Clin Liver Dis 2007, 11(1):105-117.
107. Eckard C., Cole R., Lockwood J., et al. Prospective histopathologic evaluation of lifestyle modification in nonalcoholic fatty liver disease: a randomized trial. Therap Adv Gastroenterol 2013, 6(4):249-259.
108. Sun W.H., Song M.Q., Jiang C.Q., et al. Lifestyle intervention in non-alcoholic fatty liver disease in Chengyang District, Qingdao, China. World J Hepatol 2012, 4(7):224-230.
109. Promrat K., Kleiner D.E., Neimeier H.M., et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 2010, 51(1):121-129.
110. Sanyal A.J., Chalasani N., Kowdley K.V., et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010, 362(18):1675-1685.
111. Belfort R., Harrison S.A., Brown K., et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006, 355(22):2297-2307.
112. Aithal G.P., Thomas J.A., Kaye P.V., et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology 2008, 135(4):1176-1184.
113. Neuschwander-Tetri B.A., Brunt E.M., Wehmeier K.R., et al. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 2003, 38(4):1008-1017.
114. Torres D., Jones F., Shaw J., et al. Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: a 12-month randomized, prospective, open- label trial. Hepatology 2011, 54(5):1631-1639.
115. Musso G., Cassader M., Rosina F., et al. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia 2012, 55(4):885-904.
116. Rakoski M.O., Singal A.G., Rogers M.A., et al. Meta-analysis: insulin sensitizers for the treatment of non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2010, 32(10):1211-1221.
117. Furuya C.K., de Oliveira C.P., de Mello E.S., et al. Effects of bariatric surgery on nonalcoholic fatty liver disease: preliminary findings after 2 years. J Gastroenterol Hepatol 2007, 22(4):510-514.
118. Mathurin P., Hollebecque A., Arnalsteen L., et al. Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease. Gastroenterology 2009, 137(2):532-540.
119. Mummadi R.R., Kasturi K.S., Chennareddygari S., et al. Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis. Clin Gastroenterol Hepatol 2008, 6(12):1396-1402.
120. Vilar Gomez E., Rodriguez de Miranda A., Gra Oramas B., et al. Clinical trial: a nutritional supplement Viusid, in combination with diet and exercise, in patients with nonalcoholic fatty liver disease. Aliment Pharmacol Ther 2009, 30(10):999-1009.
121. Harrison S.A., Torgerson S., Hayashi P., et al. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2003, 98(11):2485-2490.
122. Cohen D.E., Anania F.A., Chalasani N., National Lipid Association Statin Safety Task Force Liver Expert Panel An assessment of statin safety by hepatologists. Am J Cardiol 2006, 97(8A):77C-81C.
123. Athyros V.G., Mikhailidis D.P., Didangelos T.P., et al. Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study. Curr Med Res Opin 2006, 22(5):873-883.
124. Hyogo H., Ikegami T., Tokushige K., et al. Efficacy of pitavastatin for the treatment of non-alcoholic steatohepatitis with dyslipidemia: an open-label, pilot study. Hepatol Res 2011, 41(11):1057-1065.
125. Fernandez-Miranda C., Perez-Carreras M., Colina F., et al. A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease. Dig Liver Dis 2008, 40(3):200-205.
126. Basaranoglu M., Acbay O., Sonsuz A. A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis. J Hepatol 1999, 31(2):384.
127. Wouters K., van Gorp P.J., Bieghs V., et al. Dietary cholesterol, rather than liver steatosis, leads to hepatic inflammation in hyperlipidemic mouse models of nonalcoholic steatohepatitis. Hepatology 2008, 48(2):474-486.
128. Zheng S., Hoos L., Cook J., et al. Ezetimibe improves high fat and cholesterol diet-induced non-alcoholic fatty liver disease in mice. Eur J Pharmacol 2008, 584(1):118-124.
129. Yoneda M., Fujita K., Nozaki Y., et al. Efficacy of ezetimibe for the treatment of non-alcoholic steatohepatitis: an open-label, pilot study. Hepatol Res 2010, 40(6):566-573.
130. Park H., Shima T., Yamaguchi K., et al. Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease. J Gastroenterol 2011, 46(1):101-107.
131. Takeshita Y., Takamura T., Honda M., et al. The effects of ezetimibe on non-alcoholic fatty liver disease and glucose metabolism: a randomised controlled trial. Diabetologia 2014, 57(5):878-890.
132. Zvibel I., Bar-Zohar D., Kloog Y., et al. The effect of Ras inhibition on the proliferation, apoptosis and matrix metalloproteases activity in rat hepatic stellate cells. Dig Dis Sci 2008, 53(4):1048-1053.
133. Georgescu E.F., Ionescu R., Niculescu M., et al. Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis. World J Gastroenterol 2009, 15(8):942-954.
134. Goh G.B., Pagadala M.R., Dasarathy J., et al. Renin-angiotensin system and fibrosis in non-alcoholic fatty liver disease. Liver Int 2015, 35(3):979-985.
135. Adams L.A., Lymp J.F., St Sauver J., et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005, 129(1):113-121.
136. Stepanova M., Rafiq N., Younossi Z.M. Components of metabolic syndrome are independent predictors of mortality in patients with chronic liver disease: a population-based study. Gut 2010, 59(10):1410-1415.
137. Younossi Z.M., Otgonsuren M., Venkatesan C., et al. In patients with non-alcoholic fatty liver disease, metabolically abnormal individuals are at a higher risk for mortality while metabolically normal individuals are not. Metabolism 2013, 62(3):352-360.
138. Stepanova M., Rafiq N., Makhlouf H., et al. Predictors of all-cause mortality and liver-related mortality in patients with non-alcoholic fatty liver disease (NAFLD). Dig Dis Sci 2013, 58(10):3017-3023.